Multi-ligand simultaneous docking of Carica papaya leaf phytochemicals, Carpaine and Rutin, reveals multi-mechanism inhibition of cancer proteins BCL-2 and WWP1
Abstract
Cancer remains a major global health concern due to chemotherapy resistance and toxicity from high-dose treatments. To overcome these challenges, new therapeutic strategies targeting key proteins in cancer progression are essential. This study evaluates two phytochemicals, Carpaine (Car) and Rutin (Rut), from Carica papaya leaves, for their potential in enhancing cancer therapy by targeting B-cell lymphoma 2 (BCL-2) and WW domain-containing protein 1 (WWP1) proteins. We assessed their additive, ...
Description / Details
Cancer remains a major global health concern due to chemotherapy resistance and toxicity from high-dose treatments. To overcome these challenges, new therapeutic strategies targeting key proteins in cancer progression are essential. This study evaluates two phytochemicals, Carpaine (Car) and Rutin (Rut), from Carica papaya leaves, for their potential in enhancing cancer therapy by targeting B-cell lymphoma 2 (BCL-2) and WW domain-containing protein 1 (WWP1) proteins. We assessed their additive, allosteric, and synergistic effects using molecular docking, multi-ligand simultaneous docking (MLSD), molecular dynamics (MD) simulations, and MMPBSA analysis. Car and Rut showed an additive effect on BCL-2 by binding at distinct regions within the same pocket. MLSD revealed an improved binding affinity of -13.13 +/- 0.08 kcal/mol, compared with individual ligands or the commercial inhibitor Venetoclax. For WWP1, Car bound near the H-site and Rut near the Le-site, exhibiting an allosteric effect that increased Car's binding affinity in MLSD to -15.59 +/- 0.39 kcal/mol. Furthermore, Rut combined with bortezomib (Bort) demonstrated a synergistic interaction with WWP1. Binding energies were -7.64 +/- 0.156 kcal/mol for Bort, -10.26 +/- 0.07 kcal/mol for Rut, and -15.59 +/- 0.39 kcal/mol for MLSD, suggesting a more stable complex through synergy. These results suggest Car and Rut, particularly in combination with Bort, as promising candidates against cancer-related proteins BCL-2 and WWP1. Further experimental validation is warranted to explore their therapeutic potential.
Source: arXiv:2609.08547v1 - http://arxiv.org/abs/2609.08547v1 PDF: https://arxiv.org/pdf/2609.08547v1 Original Link: http://arxiv.org/abs/2609.08547v1
Please sign in to join the discussion.
No comments yet. Be the first to share your thoughts!
Sep 9, 2026
Pharmaceutical Research
Biochemistry
0